Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.55 |
| ▸ | ABL1 | P00519 | 14/20 | 0.55 |
| ▸ | HCK | P08631 | 7/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.54 |
| ▸ | EGFR | P00533 | 6/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.54 |
| ▸ | PRKDC | P78527 | 6/20 | 0.54 |
| ▸ | KDR | P35968 | 5/20 | 0.54 |
| ▸ | MTOR | P42345 | 5/20 | 0.54 |
| ▸ | EPHB4 | P54760 | 5/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.50 |
| ▸ | CSK | P41240 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16886199 | 0.90 | SRC (0.49) | SRCABL1HCKPIK3CDEGFR | |
| SCHEMBL15613688 | 0.88 | SRC (0.54) | SRCABL1HCKPIK3CDEGFR | |
| SCHEMBL15613702 | 0.86 | SRC (0.71) | SRCABL1HCKPIK3CDEGFR | |
| SCHEMBL15613560 | 0.86 | SRC (0.54) | SRCABL1HCKPIK3CDEGFR | |
| SCHEMBL16886188 | 0.85 | BTK (0.47) | SRCABL1HCKPIK3CDEGFR | |
| SCHEMBL16886196 | 0.84 | BTK (0.62) | SRCABL1HCKPIK3CDEGFR | |
| SCHEMBL16886178 | 0.84 | BTK (0.47) | SRCHCKPIK3CDEGFRPIK3CA | |
| SCHEMBL15613742 | 0.83 | SRC (0.60) | SRCABL1HCKPIK3CDEGFR | |
| SCHEMBL16886165 | 0.83 | SRC (0.55) | SRCABL1HCKPIK3CDEGFR | |
| SCHEMBL16886164 | 0.82 | BTK (0.54) | SRCABL1HCKPIK3CDEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796716-B2 | Selective inhibitors of Tec and Src protein kinase families | PHARMASCIENCE, INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE, INC. (CA) | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | TEC, SRC, LCK | SRC 2/4885ABL1 4/4885HCK 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.